PCOS Is Now PMOS: What Changed, and What Didn't

What changed, in one sentence

The label on the file. Nothing inside it.

The consensus paper announcing the change was published in The Lancet in June 2026, following a process run by the Global Name Change Consortium (Teede et al., 2026). It renames a condition that affects roughly one in eight women. It does not report new biology, new criteria, or new treatment.

That is worth saying plainly, because a rename can feel like a re-diagnosis when you read about it at 11pm. It isn’t one. You do not need new tests. You do not need to go back to your doctor. What you have today is what you had last year, described more accurately.

Why the old name had to go

“Polycystic” was wrong twice over.

The cysts are not cysts. What an ultrasound counts on a PCOS ovary is follicles — small fluid-filled sacs that each hold an immature egg. They are a normal ovarian structure present in unusual numbers, not growths that need draining or removing. The old name implied pathological ovarian cysts to anyone who read it, including a lot of clinicians outside gynaecology.

Plenty of people with the condition do not have them. The Rotterdam criteria, set in 2003 and still the basis of diagnosis, require any two of three features: irregular or absent ovulation, clinical or biochemical androgen excess, and polycystic ovarian morphology on ultrasound (Rotterdam ESHRE/ASRM Consensus Workshop Group, 2004). Two of three. You can meet the criteria with ovaries that look entirely ordinary on a scan.

The deeper problem was what the name left out. Naming the ovary put the whole condition in the gynaecology department, when insulin resistance, lipid changes, cardiovascular risk, liver involvement and psychological features sit at its centre for many people. The Lancet paper is direct about the cost: the old term obscured those features and contributed to delayed diagnosis, fragmented care, and stigma.

Where the new name came from

Not from a committee of ten people in a room.

In the same international survey, run in 2015 and repeated in 2023, 85.6% of patients and 76.1% of health professionals agreed the name should be changed. The words that scored highest for inclusion in a replacement were “endocrine” and “metabolic” — backed by 86.2% of patients and 79.6% of health professionals in 2023.

The consensus process that followed involved 56 academic, clinical and patient organisations, and iterative global surveys answered by 14,360 people with the condition and health professionals from every world region, plus modified Delphi rounds and structured workshops. The group deliberately chose accuracy over keeping the familiar acronym.

Here is what each word in the new name is carrying.

Word	What it points to
Poly-endocrine	More than one hormone system is involved — androgens, insulin signalling, and the brain–ovary signalling axis
Metabolic	Insulin resistance, blood sugar, lipids, liver and cardiovascular risk sit inside the condition, not beside it
Ovarian	The ovary is still involved — irregular ovulation and androgen production remain central
Syndrome	A cluster of features that travel together, not a single lesion or a single test result

Note what is missing: any word implying a cyst.

What changed and what did not

Item	Before	Now	Affects you?
Name of the condition	Polycystic ovary syndrome	Polyendocrine metabolic ovarian syndrome	Wording only
Acronym	PCOS	PMOS	Both are in use during the transition
Diagnostic criteria	Rotterdam-based, per the 2023 guideline	Identical	No
AMH as an ultrasound alternative	Allowed in adults since 2023	Unchanged	No
Your existing diagnosis	Valid	Valid — same condition	No re-testing needed
Medication and management	2023 guideline recommendations	Unchanged	No
The four phenotypes	Rotterdam phenotypes A–D	Unchanged	No
Records, referrals, billing codes	Filed under PCOS	Alignment with disease classification systems is under way	Expect both terms for a while
The research evidence	Published as “PCOS”	Still applies in full	Search both terms

The 2023 guideline that row three refers to carries 254 recommendations and practice points across diagnosis, metabolic risk, fertility and psychological care (Teede et al., 2023). None of them were reopened by the rename. If you want the criteria themselves rather than the naming story, that is the PMOS diagnostic criteria — the same Rotterdam framework, with AMH now permitted instead of ultrasound in adults.

Does this change anything by phenotype?

No — and that is the point worth making.

The four Rotterdam phenotypes are defined by which two or three criteria you meet, and the rename did not alter the criteria, so the phenotypes are untouched. If you were told you have the non-hyperandrogenic phenotype, or the phenotype without polycystic ovarian morphology, that is still what you have.

If anything, the new name fits the less-typical phenotypes better than the old one did. Someone diagnosed on irregular cycles plus raised androgens, with normal-looking ovaries, spent years carrying a name that described a feature they did not have. Work out which pattern fits you with the four types of PCOS — unchanged, and still the more useful question than the name.

What this means at your next appointment

Expect a transition, not a switch. The consensus paper describes a co-designed implementation strategy including a transition period, education, and alignment with health systems and disease classification — which means both terms will circulate for a while, and your records may say either.

Three practical things:

1. Say both names once. “I have PCOS — the one that’s now called PMOS.” That removes any ambiguity in ten words, and it is a fair assumption that your GP has not read the Lancet.
2. Don’t expect the code to have changed. Classification alignment is in progress, not finished. If a referral, insurance claim or prescription still says polycystic ovary syndrome, nothing is wrong.
3. Search both terms. Every study before 2026 is filed under the old name. Dropping “PCOS” from your searches would hide almost the entire evidence base.

There is a longer script for the conversation in telling your doctor about PMOS.

What the rename does not do

Honesty matters more than enthusiasm here.

It does not make the condition better understood overnight. It does not add treatments, and it does not resolve the parts of the evidence base that remain low to moderate quality — the 2023 guideline says so itself. It does not guarantee faster diagnosis; that depends on whether clinician education actually follows.

It is also not universally welcomed. A 2026 editorial in Metabol Open — expert commentary, not a study — sets out the open controversies and implementation challenges, and draws the parallel with the move from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease, which took years to filter through practice (Dalamaga, 2026). That transition is the realistic model for this one.

What the rename does do is stop the name arguing against the medicine. If the condition’s metabolic side is now in the title, it is harder for a ten-minute appointment to treat it as a purely gynaecological problem.

Your next step

Open whatever app or portal holds your medical records and check which term is on file — then leave it alone. Both are correct for the next few years, and there is nothing to fix.

Then spend the time on the question that actually changes what you do: which pattern of this condition you have. Start with the diagnosis and types section, or read why PCOS was renamed if the process behind the decision is what you came for.